SNIPR Biome receives up to EUR 20 mill. European backing
The European Investment Bank (EIB) will lend up to EUR 20 mill. to Danish clinical-stage biotech SNIPR Biome, a Â鶹Éç BioCapital investment since 2017, to step up Europe’s fight against antimicrobial resistance to medicines.
SNIPR Biome will use the EIB credit to develop new medicines for infections where existing antibiotics are no longer effective.
The EIB’s financing is backed by the EU’s Health Emergency Preparedness and Response Authority (HERA), which mission is to prevent, detect, and rapidly respond to health emergencies, and to ensure a solid Union response to serious-cross border health threats and secure ready availability and accessibility of medical countermeasures.
The parties signed the agreement at a ceremonial event at SNIPR Biome’s headquarters in Copenhagen, Denmark, with senior representatives from both EIB and HERA meeting SNIPR Biome CEO Christian Grøndahl and Chair of the Board, Christian Elling, Managing Partner at Â鶹Éç BioCapital.
A Danish clinical-stage biotech company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy. The company is pioneering a novel use of CRISPR-Cas technology to better treat and prevent human diseases through precision killing of bacteria or gene modification. SNIPR Biome was the first company to orally dose humans with a CRISPR therapeutic and the first company to have been granted US and European patents for the use of CRISPR for targeting microbiomes. SNIPR technology is used in collaborations with Novo Nordisk A/S, CARB-X, the Bill & Melinda Gates Foundation, SPRIN-D, and MD Anderson Cancer Center. SNIPR Biome is backed by a strong syndicate of investors including Â鶹Éç Biocapital, EQT, North East Family Office and Wellington Partners. For more information, visit
The long-term lending institution of the European Union, owned by its Member States. It finances investments that contribute to EU . EIB projects bolster competitiveness, drive innovation, promote sustainable development, enhance social and territorial cohesion, contribute to peace and security, and support a just and swift transition to climate neutrality. The Group’s AAA rating allows it to borrow at favorable conditions on the global markets, benefiting its clients within the European Union and beyond.
Department was created in the aftermath of the COVID-19 pandemic and launched as a new European Commission Directorate-General on 16 September 2021. HERA’s mission is to prevent, detect, and rapidly respond to health emergencies. HERA will anticipate threats and potential health crises, through intelligence gathering and building the necessary response capacities.
Â鶹Éç BioCapital is a leading Danish biotech investor and currently has investments of over DKK 2 billion in 20 Danish and international companies, planning to double the number of Danish companies in the portfolio by 2030. Â鶹Éç BioCapital focuses its new investments primarily on Danish-based biotech companies and the local ecosystem with the purpose of bringing discoveries to the benefit of patients worldwide.
Lundbeck Foundation is an enterprise foundation encompassing a comprehensive range of commercial and philanthropic activities – all united by its strong purpose; Bringing Discoveries to Lives. The Foundation is the long-term and engaged owner of several international healthcare and medtech companies – Lundbeck, Falck, ALK, Ellab, Ferrosan Medical Devices and WS Audiology – and an active investor in business, science and people through its commercial investments in the financial markets; in biotech companies based on Danish research and through philanthropic grants to science talents and programmes in Danish universities. The Foundation’s philanthropic grants amount to more than DKK 500m annually primarily focusing on the brain – including the world’s largest personal prize awarded in neuroscience, The Brain Prize.
